91.25

91.25 (-0.21%)

As of Feb 20, 2024

Blueprint Medicines Corp [BPMC]

Source: 

Company Overview

We are a global precision therapy company that is inventing life-changing medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines, AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the U.S. and Europe, and we are globally advancing multiple programs for systemic mastocytosis, or SM, lung cancer and other genomically defined cancers, and cancer immunotherapy.

CountryUS
Headquarterscambridgemassachusetts
Phone Number(617) 374-7580
Industrypharmaceutical preparations
CEOKathryn Haviland
Websiteblueprintmedicines.com